Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) recently presented positive results from its Dupixent trial for bullous pemphigoid at the AAD Annual Meeting, demonstrating its ongoing strides in addressing ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

In the current session, Regeneron Pharmaceuticals Inc. REGN is trading at $672.39, after a 0.89% decrease. Over the past month, the stock decreased by 0.97%, and in the past year, by 30.36%. With ...

As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year. The company also recently declared a quarterly dividend ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast ...

Achmea Investment Management B.V. significantly reduced its position in Regeneron Pharmaceuticals by 90.5% in the fourth ...

Learn more about whether Globus Medical, Inc. or Lantheus Holdings, Inc. is a better investment based on AAII's A+ Investor ...

Intact Investment Management Inc. bought 500 shares of Regeneron Pharmaceuticals, worth $356,000, in the 4th quarter. Several ...

For Regeneron Pharmaceuticals, average sales revenue over the last 5 years has been $15.84 Billion, so in the context of the Graham analysis the stock has impressive sales revenue. Originally the ...